While AGO1 and DGCR8 mutations conferred around 2.5 times higher risk of advanced tumor size, DROSHA mutations were 2.5 times more likely to present with poorly differentiated tumors at the time of diagnosis. This evidence concerns the gene DGCR8 and neoplasm.